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ABSTRACT 
Background: The association of age with coronary plaque dynamics is 
not well characterized.
Objectives: To analyze the effect of age on the progression of whole-
heart coronary plaque in patients who underwent serial coronary 
computed tomography angiography (CCTA).
Methods: From a multinational registry of patients who underwent serial 
CCTA, 1,153 subjects (61±5 years old, 61.1% male) aged 40~75 years old
with at least one detectable plaque were analyzed. Annualized volume 
changes of total, fibrous, fibrofatty, necrotic core, and dense calcification 
plaque components of the whole heart were compared by age quartile 
groups. Random forest analysis was used to define the relative 
importance of age on plaque volume progression.
Results: The median interval between the two CCTA was 3.3 
(interquartile range 2.6~4.8) years. The median annual volume changes 
of total plaque in each age quartile group was 7.8, 10.5, 10.8, and 
12.1mm3/year and for dense calcification, 2.5, 4.6, 5.4, and 7.1mm3/year, 
both of which demonstrated a tendency to increase by age (p-for-
trend=0.001 and <0.001, respectively). However, this tendency was not 
observed in the fibrous, fibrofatty, and necrotic core components. In the 
propensity score-matched population (n=318 per group), the annual 
change of total plaque volume (7.8 vs 11.5 mm3/year, p=0.008) and the 
dense calcification component (2.5 vs. 5.9 mm3/year, p<0.001) was 
significantly smaller in the lowest age quartile group versus the other age 
groups. Random forest analysis demonstrated that, apart from the 
baseline total plaque volume, age had a comparable importance in the 
total plaque volume progression as other traditional factors such as the 
serum lipid, sugar level and renal function.
Conclusions: The rate of annual plaque progression increases gradually 
depending on age, which is a result of the growth of dense calcification. 
Age is a significant factor in the plaque growth, the importance of which is
comparable to other traditional risk factors.
KEYWORDS:  coronary  artery  disease;  computed  tomography;  aging;
atherosclerotic plaque; disease progression.
CONDENSED ABSTRACT
The association of age with the coronary plaque dynamics is not known 
enough. In this analysis of the whole-heart coronary plaques from a 
multinational registry of patients who underwent serial CCTA, the 
annualized total plaque volume tended to increase significantly by age. 
This was mainly a result of the growth of dense calcification component 
than any other plaque components. By random forest analysis, apart from 
the baseline total plaque volume, age had a comparable importance in the
total plaque volume progression as other traditional cardiovascular factors
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such as the serum lipid, sugar level and renal function.
ABBREVIATIONS LIST
CAD = coronary artery disease
CACS = coronary artery calcium score
CCTA = coronary computed tomography angiography
CVD = cardiovascular disease
HU = Hounsfield units
IVUS = intravascular ultrasound
IQR = interquartile range
OCT = optical coherence tomography
ROC = receiver operating characteristic
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Introduction
Cardiovascular disease (CVD) is a major cause of morbidity and 
mortality in developed countries, and coronary atherosclerosis accounts 
for the most substantial proportion of CVD (1). Because age and 
dyslipidemia are important risk factors for coronary artery disease (CAD), 
several guidelines recommend the consideration of using lipid-lowering 
agents by age groups (2,3) and mainly, focuses on middle-aged groups, 
i.e. 40~75 years old. 
Age is a well-known major risk factor of CVD, which stems out from 
numerous results of multivariate analysis in a vast number of papers. 
However, only a few papers have focused on age itself as the central 
factor of CVD and moreover, the relationship between age and coronary 
atherosclerosis has not been addressed properly (4,5). Prior papers that 
report a serial follow-up of coronary plaque progression have been mainly 
based on quantitative coronary angiography, intravascular ultrasound 
(IVUS) or optical coherence tomography (OCT) (6,7), all of which carry an 
inherent limitation of selection bias for high-risk patients owing to the 
invasiveness of the methods used. Therefore, coronary CT angiography 
(CCTA) is an adequate noninvasive modality to analyze the progression of 
coronary plaque according to age in low-to-intermediate CAD risk 
population, as compared to invasive modalities such as IVUS (8). 
Importantly, the use of noninvasive imaging to analyze the progression of 
CAD is very useful because it sheds light to understanding the natural 
history of CAD in the general population.
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In this study, we postulated that it would be possible to analyze the 
effect of age on the progression of coronary plaque with a sufficiently 
large population who underwent serial CCTA. The objective of this study is
two-fold; first, we tried to analyze the rate of coronary plaque growth in 
relation to age, and second, we aimed to investigate the relative 
importance of age on coronary plaque growth in relation to other 
traditional CVD risk factors.
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Methods
Study subjects and protocol
The PARADIGM (Progression of AtheRosclerotic PlAque DetermIned 
by Computed TomoGraphic Angiography Imaging) registry is an 
international, prospective, open-label, multicenter observational registry 
that collected clinical and outcome data of patients who underwent serial 
CCTA (9). In brief, data was collected from 2,252 subjects who underwent 
clinically indicated serial CCTA at 13 sites in 7 countries between 2003 
and 2015. All subjects who were enrolled in PARADIGM registry underwent 
longitudinal CCTA using 64-rows or greater scanners with at least a 2-year 
interscan interval. Patients with at least one quantitatively non-
interpretable CCTA (n=492), no visible plaque on both baseline and follow-
up CCTA (n=262), previously revascularization treatment, whether 
percutaneous coronary intervention or coronary artery bypass graft 
(n=248), were excluded from this analysis. 
Because we wanted to concentrate the analysis to the middle-age 
group, the group of patients who are the main target of primary 
prevention in the guidelines (2), those below 40-years old (n=15) and over
75-year old (n=104) at enrollment were also excluded. Finally, 1,153 
subjects were the target population of analysis in this study (Figure 1). 
These subjects were classified into quartiles according to the age at the 
time of initial CCTA, with the 1st quartile defined as the youngest 
population and the 4th quartile the oldest. We used standardized 
definitions for the cardiovascular risk factor (9). Our study data including 
7
demographics, medical history, laboratory data and the occurrence of 
clinical events were collected prospectively within one month from the 
initial and subsequent CCTA (9). The study was approved by the 
institutional review boards of all participating centers.
CCTA protocol and the image analysis
All CCTA scans were done in accordance with the Society of 
Cardiovascular Computed Tomography guidelines (10,11). All CCTA 
datasets from participating centers were transferred to the core laboratory
for blinded image analysis. Coronary atherosclerotic plaque analysis was 
performed by level III experienced reader using semi-automated software 
(QAngioCT Research Edition v2.1.9.1; Medis Medical Imaging Systems, 
Leiden, the Netherlands) with manual correction (8). All coronary artery 
segments with a diameter ≥2mm were analyzed using a modified 17-
segment American Heart Association model (11). Atherosclerosis on CCTA 
was defined as any tissue ≥1mm2 within or adjacent to the lumen 
identified in >2 planes that could be differentiated from the surrounding 
intrathoracic tissue such as the epicardial fat or the pericardium (11). 
Plaque volumes (mm3) of all coronary segments were acquired and then 
summated to create the total plaque volume on the per-patient level. The 
annual change of plaque volume was defined as the difference between 
baseline and follow-up plaque volume divided by the time interval 
between the serial CT studies. The atherosclerotic plaque was further 
subclassified by composition, using pre-defined intensity cutoff values in 
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Hounsfield units (HU) for necrotic core (-30 to 30HU), fibrofatty (31 to 
130HU), fibrous (131 to 350HU), and dense calcification (≥351HU) 
components (12,13). The mean plaque burden was calculated as follows: 
[(the plaque volume of the entire vessels / the entire vessel volume) x100]
(%).
Study endpoint
The primary endpoint of the current study is the annual change of 
the total plaque volume and each plaque component volume between the 
serial CCTAs. The rate of plaque volume and each component changes 
were compared between each age quartile groups. 
Statistical analysis
Continuous variables are presented as mean±standard deviation or
median [interquartile range (IQR)], depending on whether normality is 
satisfied by the Shapiro-Wilk test. Categorical variables are shown as 
absolute counts (percentage). The comparison of categorical variables 
was done using a Chi-square test or Fisher’s exact test and that of the 
continuous variables using Student’s t-test or Mann-Whitney U-test, as 
appropriate. The trend of the change in plaque volume according to age 
groups was analyzed by the Cochran–Armitage test. To reduce the effect 
of the difference in baseline characteristics other than the age, we 
adjusted for differences in baseline characteristics of patients using 
propensity score matching with the greedy nearest matching technique
9
(14). All variables of absolute standardized mean difference ≥0.1, 
including the statin medication, were used for propensity score matching 
analysis (Supplementary Table 1) and the subjects from the 2nd~4th age 
quartile groups were 1:1 matched to those in the 1st age quartile group.
Random forest analysis (15) was used to identify the importance of 
age in the rapid progression of total plaque progression, defined as the 
total plaque volume progression larger than the median value. We divided 
the total population into the derivation (65%) and the validation 
population (35%). Random forest analysis was done with 5-fold internal 
cross-validation with the data from the derivation population. We validated
the optimized model created from the derivation cohort using the receiver
operating characteristic (ROC) analysis in the validation cohort. The 
importance of each variables in the random forest analysis was calculated
using the classification error for the random forest trees and the error 
after permuting the predictor variables (15). All statistical analyses were 
performed using the Statistical Package for the Social Sciences (SPSS) 
20.0 (IBM Co., Armonk, NY, USA) or R version 3.6.0 software (R 
Development Core Team, Vienna, Austria), and a two-tailed p-value <0.05 
was considered significant for all analysis.
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Results
Baseline demographic characteristics of the study participants
Among the 1,153 patients (mean age, 60.4±7.7 years), 61% 
(n=705) were male. There were 255 diabetes patients (22%). The 
participants were classified into quartiles according to age at the initial 
CCTA; Q1, 40~55 years old; Q2, 56~61; Q3, 62~66; and Q4, 67~75 
(Supplementary Figure 1). The baseline clinical characteristics are 
compared between the four age groups (Table 1). The lowest age quartile
group (Q1) had a higher proportion of males, current smoker but lower 
systolic blood pressure and the prevalence of traditional cardiovascular 
risk factors in general. The proportion of patients taking antiplatelet 
agents or antihypertensives was also the lowest in the lowest age quartile 
group. The same group had a higher glomerular filtration rate and total 
cholesterol, triglyceride, and low density lipoprotein-cholesterol.
Baseline plaque volume and its changes according to age
The median interval between the two CCTA examinations was 3.3 
years (IQR 2.6 to 4.8 years). There was no difference in the time interval 
between the two CCTA examinations between the four age quartile groups
(Table 1). 
At the initial CCTA examination, the median total plaque volume 
was 65.2mm3/year (IQR 22.0~160.6) and the median mean plaque burden
3.0% (IQR 1.1~7.5) in the entire population. The total plaque volume, as 
well as the fibrous and dense calcification component volume and the 
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mean plaque burden at baseline was the lowest in the lowest age quartile 
group. There was a significant trend towards an increase of the above 
parameters across the age quartile groups (all p-for-trend=0.001) (Table 
2). However, the fibrofatty and the necrotic core component volume did 
not differ between the age quartile groups nor were there trends across 
the age groups (Supplementary Figure 2).
As for the annual change of the coronary plaques, the median total 
plaque volume change per year was 10.0mm3/year (IQR 3.6~23.2) in the 
entire population. The annual change of the total plaque, dense calcified 
component volume, and the mean plaque burden were the lowest in the 
lowest age quartile group. The same parameters demonstrated a 
significant trend towards an increase across the age quartile groups (all p-
for-trend<0.001; Figure 2). However, there was no significant association
of age with the change of fibrous, fibrofatty and necrotic core components
across the four age quartile groups.
Baseline plaque volume and its changes in the propensity score-
matched population 
To analyze the sole effect of age on coronary plaques, we adjusted 
for differences in baseline characteristics using the propensity score 
matching. The propensity matching results were satisfactory, with no 
difference in any baseline characteristics other than age 
(Supplementary Table 1). 
The annual change of total plaque, dense calcification component 
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volume, and the mean plaque burden was significantly lower in the lowest
age quartile group compared with the other age quartile groups. This 
trend did not change after propensity score matching (Table 3, Figure 3).
However, there was no significant difference in the change of fibrous, 
fibrofatty and necrotic core components between the lowest age quartile 
group versus the other age quartile groups.
Relative importance of age in coronary plaque progression in 
comparison with other cardiovascular risk factors
Using random forest analysis, we analyzed how important age 
would be in predicting the rapid coronary plaque progressors, defined as 
those with the total plaque volume progression larger than the median 
value, in relation to other cardiovascular risk factors. The best predictive 
random forest model using the derivation cohort was built on a model of 
ntree 2000, with an area under the curve of 0.75 (95% confidence interval
0.70 to 0.79) when tested on the validation dataset. 
Apart from the baseline total plaque volume, which was the most 
crucial factor in predicting the rapid progressors, age was as crucial as 
other cardiovascular risk factors, such as body mass index, serum 
glucose, and serum lipid level (Figure 4). More specifically, assuming that
the importance of baseline total plaque volume is 100, the relative 
importance of age at the initial CCTA examination was 27. The relative 
importance of most of the traditional cardiovascular risk factors ranged 
from 23 to 29, which were similar with that of age (Supplementary 
13
Table 2).
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Discussion
The present study of a large cohort of patients who underwent two 
serial CCTAs demonstrated that age is significantly associated with the 
growth of coronary plaque burden in the whole heart. This trend in the 
increase of coronary atherosclerosis by age is largely and significantly 
driven by the increase in the amount of calcified plaque. Although the 
baseline degree of coronary atherosclerosis is the sole important factor 
associated with the growth of coronary plaque, age was as important as 
any other traditional cardiovascular risk factors. These findings 
demonstrate that the contribution of age to coronary atherosclerosis is not
because of the comorbidities associated with aging but age itself as a 
significant risk factor.
The association between age and rate of total plaque volume 
progression 
Annual changes of the total plaque volume in the serial CCTAs of 
the present study were different between the age quartile groups, and the
lowest quartile had a significantly slower progression rate than the other 
age groups. A recent analysis done with the CCTA suggested that age 
predicts future major adverse cardiovascular events (4). The present 
study is the first large prospective multi-ethnic observational registry to 
identify that the rate of plaque progression on CCTA increases with age, 
demonstrating a possible mechanism of the previous study. 
Atherosclerosis is a dynamic process with chronic inflammation as 
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the most critical molecular and cellular mechanism (16). Persistent 
hypercholesterolemia in isolation does not cause atherosclerosis, but the 
age-associated exhaustion of the progenitor cells is a determinant of 
atherosclerosis in animal models (17). Recently, clonal hematopoiesis of 
indeterminate potential (CHIP), a clonal expansion of hematopoietic stem 
cells, has been shown to be a predictor of various cardiovascular diseases
(18). The prevalence of CHIP is associated with aging, and the function of 
progenitor cells is bound to decline with age (19). These previous findings 
may provide a plausible cellular mechanism of why aging itself is 
associated with the progression of coronary atherosclerosis in our 
analysis.
Age and calcified plaque volume progression – the mechanism 
and clinical significance
Calcified plaque refers to the progression of microscopic calcium 
deposition in the atherosclerotic plaque to more massive sheets or plates 
that could be detected macroscopically (20). There are several complex 
inhibitory mechanisms against the formation of calcified plaque in the 
baseline atherosclerotic lesion (20-23). The plasma level of Klotho, which 
is a protein that inhibits vascular calcification by decreasing the 
expression of phosphate transporter 1 (PiT1) in the vascular smooth 
muscle cell membrane, declines with age (23). Matrix Gla protein (MGP), a
member of the family of vitamin-K2 dependent protein, is a potent 
inhibitor of vascular calcification, the inactive form of which increases with
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age and is a significant predictor of vascular calcification (24). These 
suggest that there are various anti-calcific molecular mechanisms that 
decreases with age and that the increase of calcified plaque in the older 
age groups may be explained by the failure of these anti-calcific molecular
mechanisms. 
The coronary artery calcium score (CACS) has been used for risk 
stratification in the primary prevention of CVD because it predicts future 
major adverse cardiovascular events in patients at intermediate risk
(2,25). The progression of CACS demonstrates an exponential increase 
with age in the middle age group with no history of CAD (26). In a previous
study, the increase in CACS showed a statistically significant positive 
correlation with the increase in the total and calcified plaque (27). Our 
findings emphasizes these previous findings that the increase in the 
calcified plaque component by age is significantly associated with the 
increase in the total coronary atheroma burden of the whole heart. Based 
on our analysis, patients with a more advanced age would be expected to 
have a more rapid progression of total and calcified plaque than that of 
the younger patients with a similar value of CACS at baseline. 
Relative importance of age in coronary plaque progression
Several algorithms have been designed to interprete traditional risk
factors for CVD and to provide individual risk scores, where age has 
always been included in risk evaluation for CVD (2,28,29). Keeping all 
other variables constant, increase of the age elevates the risk of CVD 
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abruptly in these algorisms (5). With the random forest analysis in our 
study, we could also specify that age was an essential factor in rapid 
plaque progression along with, and indepently of other traditional 
cardiovascular risk factors. 
Aging is a complex process that is associated with various changes 
in the homeostatic mechanism of the body. Therefore, it is very difficult to 
analyze the effect of age in isolation. Some investigators have 
emphasized that age may be a ‘modifiable’ risk factor for CVD (30), which 
stems from the fact that the prevalence of comorbidities/risk factors 
increases with age and that age reflects the time-related exposure to 
numerous cardiovascular risk factors. However, a recent study of Tsimane 
subjects with very few cardiovascular risk factors have also pointed to the 
significant association of age with CACS (31). The association of age with 
atherosclerosis has also been demonstrated in the preindustrial 
population as well (32). These findings indicate that we do not completely 
understand the effect of age on coronary plaque progression but directs 
us to future research in understanding the association of age with 
potential modifiable situations. For example, the age-associated decrease 
in the antioxidant effect may be a potential mechanism and a possible 
therapeutic option that should be pursued in the future (33).
Limitation
Our study has some limitations. First, since this is an observational 
registry designed to investigate the natural course of the low-intermediate
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risk population of coronary artery atherosclerosis, a possible selection bias
could not be avoided, and therefore, the difference in annual changes of 
plaque volume in high-risk acute coronary syndrome patients could not be
demonstrated. Second, statin might be a confounding factor that 
mediates the association between age and calcified plaque progression. A 
recent study suggests that statin use is associated with a higher rate of 
calcified plaque volume progression (27), and the elderly patients were 
more likely to take statins. However, we demonstrated that the older age 
group still has a higher plaque progression rate even after rigorous 
propensity score matching. This means that age is an independent risk 
factor for calcified plaque progression, regardless of the statin use.
Conclusion
The rate of annual coronary plaque volume progression increases 
significantly with age. The dense calcification plaque component is the 
main component that explains the growth of coronary plaques by age. The
mechanism of why age is a significant predictor of coronary plaque 
progression warrants further investigations in the future.
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PERSPECTIVES
Clinical Competencies: Age is a significant risk factor of incident 
cardiovascular disease. Using CCTA for the quantitative plaque analysis of 
the whole heart, age was significantly associated with coronary plaque 
growth, the relative importance of which is comparable to other traditional
cardiovascular risk factors such as serum sugar or lipid level. 
Translational Outlook: Although the age-associated progression of 
coronary atherosclerosis may be explained partially by a longer term 
exposure to cardiovascular risk factors, further studies are needed to 
identify the mechanism of why age is related to the progression of 
coronary atherosclerosis, which may lead us to the development of novel 
therapeutics.
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Figure legend
Central illustration. Comparison of coronary plaque progression 
between the older and younger subjects on serial coronary 
computed tomography angiography images.
(A) A 69-year-old subject with significant changes of the total plaque 
volume (38.4mm3/year). (B) A 54-year-old subject with minimal changes of
the total plaque volume (5.3mm3/year). (C) Significant trend in the 
increase of annualized coronary plaque volume progression by age.
Figure 1. Flow chart of the study participants. 
CCTA, coronary computed tomography angiography; PCI, percutaneous 
coronary intervention; CABG, coronary artery bypass graft.
Figure 2. Annualized change rate of whole-heart coronary plaque 
and its components between the serial CCTAs according to age 
quartile groups.
Values are presented as median+standard error. (A) Annual change of 
total plaque volume per patient (mm3/year). (B) Annual change of fibrous 
plaque volume (mm3/year). (C) Annual change of calcified plaque volume 
(mm3/year). (D) Annual change of mean plaque burden (%/year). CCTA, 
coronary computed tomography angiography. Q1 (quartile 1), 40~55; Q2 
(quartile 2), 55~61; Q3 (quartile 3), 61~66; Q4 (quartile 4), 66~75 years 
old.
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Figure 3. Annualized change rate of whole-heart coronary plaque 
and its components between the serial CCTAs in the propensity 
score matched cohort. 
The entire population was 1:1 matched between the 1st age quartile group
versus the 2nd~4th quartile groups. Values are presented as 
median+standard error. (A) Annual change of total plaque volume per 
patient (mm3/year). (B) Annual change of fibrous plaque volume 
(mm3/year). (C) Annual change of calcified plaque volume (mm3/year). (D)
Annual change of mean plaque burden (%/year). CCTA, coronary 
computed tomography angiography. Q1 (quartile 1), 40~55; Q2 (quartile 
2), 55~61; Q3 (quartile 3), 61~66; Q4 (quartile 4), 66~75 years old.
Figure 4. Random forest analysis results for the analysis of 
relative variable importance in predicting rapid plaque 
progressors. 
Among the 31 variables, only the top 20 important variables are shown. 
The importance of the most significant variable, baseline total plaque 
volume, was set as 100 and the relative importance of each variables 
were compared. LDL, low-density lipoprotein; GFR (CKD-EPI), glomerular 
filtration rate (chronic kidney disease – epidemiology collaboration); TG, 
triglyceride; HDL, high-density lipoprotein; BMI, body mass index; CT, 
computed tomography; SLNG, sublingual nitroglycerin; CVD, 
cardiovascular disease.
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Table 1. Baseline characteristics comparison between the age 
quartile groups at the time of baseline CCTA. 
Entire
populati
on
(N=1,15
3)
Quartile
1
(N=318)
Quartile
2
(N=279)
Quartile
3
 (N=271
)
Quartile
4
(N=285)
p-
valu
e
Age, years 60.4 ±7.7
50.4 ±
3.9
58.7 ±
1.7
64.0 ±
1.4
69.8 ±
2.2
<0.0
01
Male, n (%)  705(61.1%)
225
(70.8%)
172
(61.6%)
163
(60.1%)
145
(50.9%)
<0.0
01
Ethnicity 0.412
  African            1 (0.1%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.4%)
  Caucasian     315(27.3%)
77
(24.2%)
71
(25.4%)
77
(28.4%)
90
(31.6%)
  East Asian          795(69.0%)
232
(73.0%)
195
(69.9%)
183
(67.5%)
185
(64.9%)
  Latin American   41 (3.6%) 9 (2.8%) 12 (4.3%) 11 (4.1%) 9 (3.2%)
  South Asian 1 (0.1%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 0 (0.0%)
BMI, kg/m2          25.5 ±3.2
25.8 ±
3.1
25.8 ±
3.3
25.2 ±
3.1
25.2 ±
3.4
0.03
0
SBP, mmHg        130.2 ±16.3
127.3 ±
16.2
130.1 ±
15.2
131.4 ±
16.6
132.3 ±
16.9
<0.0
01
DBP, mmHg 78.7 ±9.9
79.6 ±
10.6
78.9 ±
9.9
79.0 ±
9.2
77.3 ±
9.6
0.01
8
Cardiovascular risk 
factors, n (%)
Hypertension 632(54.8%)
134
(42.1%)
153
(54.8%)
163
(60.1%)
182
(63.9%)
<0.0
01
Diabetes mellitus 255(22.1%)
54
(17.0%)
68
(24.4%)
62
(22.9%)
71
(24.9%)
0.06
9
Dyslipidemia 485(42.1%)
128
(40.3%)
121
(43.4%)
117
(43.2%)
119
(41.8%)
0.85
6
Atrial fibrillation  67 (5.8%) 11 (3.5%) 14 (5.0%) 14 (5.2%) 28 (9.8%) 0.007
Familial history 
of CAD          
326
(28.3%)
101
(31.8%)
81
(29.0%)
72
(26.6%)
72
(25.3%)
0.30
2
Stroke 58 (5.0%) 5 (1.6%) 12 (4.3%) 19 (7.0%) 22 (7.7%) 0.00
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Entire
populati
on
(N=1,15
3)
Quartile
1
(N=318)
Quartile
2
(N=279)
Quartile
3
 (N=271
)
Quartile
4
(N=285)
p-
valu
e
2
Current smoker 221(19.2%)
85
(26.7%)
61
(21.9%)
42
(15.5%)
33
(11.6%)
<0.0
01
Medication history, n (%)
Antiplatelet 
agents
483
(41.9%)
97
(30.5%)
126
(45.2%)
124
(45.8%)
136
(47.7%)
<0.0
01
RAS blockade      348(30.2%)
80
(25.2%)
85
(30.5%)
97
(35.8%)
86
(30.2%)
0.04
9
Beta blocker 327(28.4%)
71
(22.3%)
63
(22.6%)
83
(30.6%)
110
(38.6%)
<0.0
01
CCB 263(22.8%)
52
(16.4%)
61
(21.9%)
68
(25.1%)
82
(28.8%)
0.00
3
Diuretics 103(8.9%) 19 (6.0%) 21 (7.5%) 26 (9.6%)
37
(13.0%)
0.01
9
Nitrate       95 (8.2%) 17 (5.3%) 25 (9.0%) 24 (8.9%) 29(10.2%)
0.15
4
Statins    543(47.1%)
127
(39.9%)
128
(45.9%)
133
(49.1%)
155
(54.4%)
0.00
4
Oral 
hypoglycemics 
112
(9.7%) 26 (8.2%) 22 (7.9%)
33
(12.2%)
31
(10.9%)
0.2
37
Laboratory 
findings
GFR, 
mL/min/1.73m2
78.7
[67.8–
89.3]
84.4
[74.1–
96.6]
81.7
[70.7–
93.6]
77.5
[64.7–
88.6]
74.3
[65.0–
83.5]
<0.0
01
Glucose, mg/dL
101.0
[94.0–
111.0]
101.0
[94.0–
110.0]
101.0
[94.8–
112.0]
100.4
[94.0–
111.0]
101.0
[94.0–
109.0]
0.97
0
Total cholesterol, 
mg/dL
187.0
[167.0–
213.0]
192.0
[174.0–
220.0]
185.0
[164.0–
209.3]
188.0
[165.0–
213.0]
182.0
[166.0–
210.0]
0.00
1
HDL cholesterol, 
mg/dL
49.0
[42.0–
57.0]
47.0
[42.0–
56.0]
48.5
[41.0–
55.9]
49.9
[43.0–
57.5]
49.5
[42.0–
58.0]
0.15
8
Triglyceride, mg/
dL
134.0
[96.0–
176.0]
149.9
[97.0–
199.3]
130.0
[95.0–
171.5]
131.0
[95.5–
171.6]
125.0
[95.0–
157.0]
<0.0
01
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Entire
populati
on
(N=1,15
3)
Quartile
1
(N=318)
Quartile
2
(N=279)
Quartile
3
 (N=271
)
Quartile
4
(N=285)
p-
valu
e
LDL cholesterol, 
mg/dL
113.0
[93.5–
136.0]
119.0
[99.4–
142.0]
111.0
[92.0–
133.0]
115.0
[93.0–
136.0]
110.5
[92.6–
132.0]
0.00
2
CCTA interval  3.8 ± 1.6  3.9 ± 1.7  3.7 ± 1.4  3.9 ± 1.7  3.8 ± 1.5 0.655
Categorical variables are presented as the number (percent). Continuous 
variables are presented as mean±standard deviation or median 
[interquartile range], as appropriate. The age group was classified by 
quartiles, Quartile 1, 40~55 years old; Quartile 2, 55~61; Quartile 3, 
61~66; Quartile 4, 66~75. BMI, body mass index; SBP, systolic blood 
pressure; DBP, diastolic blood pressure; CAD, coronary artery disease; 
RAS, renin-angiotensin system; CCB, calcium channel blocker; GFR, 
glomerular filtration rate; HDL, high-density lipoprotein; LDL, low-density 
lipoprotein; CCTA, Coronary computed tomography angiography.
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Table 2. Baseline and annual changes of the whole-heart coronary
plaque and its components between the serial CCTAs.
Entire
populat
ion
(N=1,1
53)
Quartil
e 1
(N=318
)
Quartil
e 2
(N=279
)
Quartil
e 3
 (N=27
1)
Quartil
e 4
 (N=28
5)
p
for
tre
nd
Baseline CCTA analysis of the whole-heart 
coronary plaques
Total plaque volume 
(mm3)
65.2
[22.0–
160.6]
49.4
[10.5–
128.0]
65.6
[21.8–
153.8]
70.4
[24.7–
150.6]
82.4
[28.8–
198.8]
<0.
001
Fibrous component 
volume (mm3)
28.6
[9.7–
67.0]
21.7
[6.2–
52.1]
31.0
[9.7–
66.6]
29.6
[10.8–
70.1]
31.9
[12.7–
83.6]
0.00
1
Fibrofatty component
volume (mm3)
 6.9 [0.5–
26.5]
 7.5 [0.2–
31.7]
 7.9 [0.4–
29.6]
 6.0 [0.5–
23.2]
 6.1 [0.8–
23.1]
0.09
4
Necrotic core 
component volume 
(mm3)
 0.1 [0.0–
1.8]
 0.1 [0.0–
2.3]
 0.2 [0.0–
2.1]
 0.1 [0.0–
1.1]
 0.1 [0.0–
1.8]
0.13
2
Dense calcification 
component volume 
(mm3)
12.4
[1.0–
43.8]
 3.2 [0.0–
23.7]
12.9
[1.4–
36.6]
17.3
[2.5–
51.1]
26.8
[6.2–
75.3]
<0.
001
Fibrofatty + necrotic 
core component 
volume (mm3)
 7.2 [0.5–
30.5]
 7.9 [0.2–
34.7]
 8.1 [0.4–
34.8]
 6.2 [0.6–
26.4]
 6.2 [0.8–
26.9]
0.08
7
Non-calcified 
component volume 
(mm3)
40.8
[11.8–
108.9]
35.2
[8.1–
93.6]
42.5
[11.4–
108.6]
42.8
[17.2–
102.7]
45.9
[15.1–
118.5]
0.11
7
Mean plaque burden 
(%)
 3.0 [1.1–
7.5]
 2.1 [0.6–
5.5]
 3.1 [1.1–
7.5]
 3.4 [1.3–
6.8]
 4.9 [1.4–
10.3]
<0.
001
Annual changes of the whole-heart plaque volume and its 
components
Total plaque volume 
(mm3/year)
10.0
[3.6–
23.2]
 7.8 [3.0–
18.5]
10.4
[3.7–
23.9]
10.8
[4.3–
24.2]
12.1
[4.4–
28.1]
0.00
1
Fibrous component 
volume (mm3/year)
 3.0 [0.0–
9.5]
 3.0 [0.6–
8.1]
 4.3 [0.6–
11.2]
 2.6 [-
0.7–9.4]
 2.8 [-
0.7–9.9]
0.36
3
Fibrofatty component
volume (mm3/year)
 0.0 [-
1.2–2.1]
 0.0 [-
1.6–2.1]
 0.1 [-
1.0–2.2]
 0.0 [-
1.2–1.8]
 0.0 [-
0.8– 2.1]
0.61
7
Necrotic core  0.0 [-  0.0 [0.0–  0.0 [-  0.0 [0.0–  0.0 [0.0– 0.44
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Entire
populat
ion
(N=1,1
53)
Quartil
e 1
(N=318
)
Quartil
e 2
(N=279
)
Quartil
e 3
 (N=27
1)
Quartil
e 4
 (N=28
5)
p
for
tre
nd
component volume 
(mm3/year) 0.1–0.1] 0.2] 0.1–0.1] 0.1] 0.1] 4
Dense calcification 
component volume 
(mm3/year)
 4.7
[ 1.2–
13.0]
 2.5 [0.6–
8.1]
 4.6 [1.0–
11.6]
 5.4 [1.7–
14.9]
 7.1 [2.6–
19.0]
<0.
001
Fibrofatty + necrotic 
core component 
volume (mm3/year)
 0.0 [-
1.2–2.3]
 0.0 [-
1.7–2.4]
 0.1 [-
1.2–2.3]
 0.0 [-
1.2–1.7]
 0.0 [-
1.0–2.3]
0.77
4
Non-calcified 
component volume 
(mm3/year)
 3.1 [-
0.8–11.2]
 3.1 [-
0.3–9.5]
 4.2 [0.1–
13.2]
 1.4 [-
2.3–10.6]
 3.1 [-
1.0–12.1]
0.40
6
Mean plaque burden 
(%/year)
 0.5 [0.2–
1.1]
 0.3 [0.1–
0.9]
 0.5 [0.2–
1.3]
 0.5 [0.2–
1.1]
 0.6 [0.2–
1.3]
<0.
001
Variables are presented as median [interquartile range]. Age group was 
classified by 4 quartiles, Quartile 1, 40~55 years old; Quartile 2, 55~61; 
Quartile 3, 61~66; Quartile 4, 66~75. CCTA, coronary computed 
tomography angiography.
33
Crude population Propensity-matched population
Quartile
1
(N=318)
Quartiles
2~4
(N=835)
p-
valu
e
Quartile
1
(N=318)
Quartiles
2~4
(N=318)
p-
valu
e
Baseline CCTA 
analysis
Total plaque volume 
(mm3)      
49.4
[10.5–
128.0]
73.2
[26.0–
169.1]
<0.0
01
49.4
[10.5–
128.0]
71.1
[23.1–
160.6]
0.00
3
Fibrous component 
volume (mm3)     
21.7
[6.2–
52.1]
30.6
[11.3–
73.4]
<0.0
00
21.7
[6.2–
52.1]
29.1
[10.0–
65.9]
0.01
1
Fibrofatty component 
volume (mm3)
7.5
[0.2–
31.7]
6.6
[0.5–
25.5]
0.72
5
7.5
[0.2–
31.7]
5.4
[0.4–
22.4]
0.44
6
Necrotic core 
component volume 
(mm3)
0.1
[0.0– 2.3]
0.1
[0.0–1.7]
0.90
5
0.1
[0.0– 2.3]
0.1
[0.0–1.7]
0.68
8
Dense calcification 
component volume 
(mm3)
3.2
[0.0–
23.7]
17.3
[2.6–
52.8]
<0.0
01
3.2
[0.0–
23.7]
16.4
[1.6–
49.2]
<0.0
01
Fibrofatty + necrotic 
core component 
volume (mm3)
7.9
[0.2–
34.7]
6.8
[0.6–
27.8]
0.70
3
7.9
[0.2–
34.7]
5.6
[0.4–
26.2]
0.45
0
Non-calcified 
component volume 
(mm3)
35.2
[8.1–
93.6]
43.5
[14.8–
111.1]
0.01
9
35.2
[8.1–
93.6]
38.4
[12.1–
117.2]
0.17
1
Mean plaque burden 
(%)
2.1
[0.6–5.5]
3.7
[1.2– 8.4]
<0.0
01
2.1
[0.6– 5.5]
3.4
[1.1– 8.4]
<0.0
01
Annual changes of 
plaque
Total plaque volume 
(mm3/year)
7.8
[3.0–
18.5]
11.1
[4.1–
25.1]
0.00
1
7.8
[3.0–
18.5]
10.7
[3.8–
25.7]
0.01
4
Fibrous component 
volume (mm3/year)     
3.0
[0.6–8.1]
3.1 [-
0.3–10.0]
0.55
7
3.0
[0.6–8.1]
3.0 [-
0.3–10.0]
0.77
1
Fibrofatty component 
volume (mm3/year)
0.0 [-
1.6–2.1]
0.0 [-
1.0–2.1]
0.97
8
0.0 [-
1.6–2.1]
0.0 [-
1.1–1.7]
0.78
1
Necrotic core 
component volume 
(mm3/year)
0.0 [-
0.0–0.2]
0.0 [-
0.1–0.1]
0.22
9
0.0 [-
0.0–0.2]
0.0 [-
0.1–0.1]
0.05
1
Dense calcification 
component volume 
(mm3/year)
2.5
[0.6–8.1]
5.9
[1.6–
15.1]
<0.0
01
2.5
[0.6–8.1]
6.0
[1.3–
15.1]
<0.0
01
Fibrofatty + necrotic 
core component 
volume (mm3/year)
0.0 [-
1.7–2.4]
0.0 [-
1.2–2.3]
0.79
2
0.0 [-
1.7–2.4]
0.0 [-
1.2–1.8]
0.57
1
Non-calcified 
component volume 
(mm3/year)
3.1 [-
0.3–9.5]
3.1 [-
0.9–12.2]
0.57
3
3.1 [-
0.3–9.5]
2.8 [-
0.7–12.3]
0.62
2
34
Mean plaque burden 
(%/year)
0.3
[0.1–0.9]
0.6
[0.2–1.2]
<0.0
01
0.3
[0.1–0.9]
0.5
[0.2–1.3]
0.00
1
Table  3.  Changes  of  whole-heart  coronary  plaque  and  its
components  plaque  between  the  lowest  age  quartile  and  the
other age groups.
Variables are presented as median [interquartile range]. Age group was 
classified by 4 quartiles, Quartile 1, 40~55 years old; Quartile 2, 55~61; 
Quartile 3, 61~66; Quartile 4, 66~75. CCTA, coronary computed 
tomography angiography.
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